Saad Z. Usmani, MD, MBA, FACP, on Response Rates From CARTITUDE-1 Trial at 2021 ASCO
Usmani detailed the primary results from CARTITUDE-1, focusing on overall response rate and stringent complete responses.
Saad Z. Usmani, MD, MBA, FACP, on Intriguing Data for High-Risk Multiple Myeloma at 2021 ASCO
Usmani highlighted the FORTE study as one of the trials investigating the high-risk cohort of patients.
Saad Z. Usmani, MD, MBA, FACP, Details the Safety Profile for CARTITUDE-1 Trial
Usmani discussed the common adverse events observed from CARTITUDE-1, including hematologic events and cytokine release syndrome.
Saad Z. Usmani, MD, MBA, FACP, Talks About Durable and Deep Responses of Cilta-Cel for Patients With Multiple Myeloma
Usmani noted the strong overall response and stringent complete response rates observed with ciltacabtagene autoleucel for multiple myeloma at a median follow-up of 18 months.